Cargando…
Targeting SARS-CoV-2 papain-like protease in the postvaccine era
While vaccines remain at the forefront of global healthcare responses, pioneering therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid development and approval of orally available direct-acting antivirals targeting crucial SARS-CoV-2 proteins marked the beginning...
Autores principales: | Ton, Anh-Tien, Pandey, Mohit, Smith, Jason R., Ban, Fuqiang, Fernandez, Michael, Cherkasov, Artem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399131/ https://www.ncbi.nlm.nih.gov/pubmed/36114026 http://dx.doi.org/10.1016/j.tips.2022.08.008 |
Ejemplares similares
-
In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
por: Huynh, Tien, et al.
Publicado: (2021) -
Deubiquitinating Activity of the SARS-CoV Papain-Like Protease
por: Barretto, Naina, et al.
Publicado: (2006) -
Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus Deep Docking of 40 billion small molecules
por: Gentile, Francesco, et al.
Publicado: (2021) -
Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site
por: Lee, Jaeyong, et al.
Publicado: (2020) -
Crystal structure of SARS-CoV-2 papain-like protease
por: Gao, Xiaopan, et al.
Publicado: (2021)